SCHEMBL21652053

SCHEMBL21652053

CCN1CCC(NC(=O)c2ncccc2F)C1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM5A P29375 1/20 0.55
HTR4 Q13639 1/20 0.44
NPC1 O15118 1/20 0.44
L3MBTL1 Q9Y468 1/20 0.44
ACSS2 Q9NR19 2/20 0.43
SSTR4 P31391 1/20 0.43
PKM P14618 1/20 0.43
MEN1 O00255 1/20 0.43
KMT2A Q03164 1/20 0.43
RECQL P46063 1/20 0.43
RET P07949 1/20 0.43
DRD2 P14416 2/20 0.43
HTR1A P08908 1/20 0.43
HTR7 P34969 1/20 0.43
HTR6 P50406 1/20 0.43
HRH2 P25021 1/20 0.43
HRH1 P35367 1/20 0.43
DRD4 P21917 1/20 0.43
WNT1 P04628 1/20 0.42
DYRK1A Q13627 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20068957 0.84 KDM5A (0.57) KDM5ASSTR4WNT1DYRK1A
SCHEMBL20147609 0.82 KDM5A (0.56) KDM5ASSTR4RETWNT1DYRK1A
SCHEMBL20205999 0.79 HTR7 (0.61) NPC1L3MBTL1MEN1KMT2ADRD2
SCHEMBL3462177 0.78 HRH2 (0.41) HTR4ACSS2MEN1KMT2AHRH2
SCHEMBL28488542 0.77 ALDH1A1 (0.58) KDM5AMEN1KMT2A
SCHEMBL19215315 0.76 ALDH1A1 (0.64) KDM5ANPC1MEN1KMT2A
SCHEMBL22722011 0.74 ELANE (0.49) KDM5A
SCHEMBL12436726 0.74 ELANE (0.49) KDM5A
SCHEMBL3462118 0.72 HRH2 (0.63) KDM5ANPC1HRH2HRH1
SCHEMBL21651996 0.72 RET (0.50) SSTR4RET

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20200383966-A9 SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS ARRAY BIOPHARMA INC (US) 2020-12-10 US disclosed
US-20200030311-A1 SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS ARRAY BIOPHARMA, INC. 2020-01-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200383966-A9 SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS RET, BRAF, RAF1 KDM5A 902/4885HTR4 3337/4885NPC1 4145/4885
US-20200030311-A1 SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS RET, BRAF, RAF1 KDM5A 902/4885HTR4 3337/4885NPC1 4145/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.